Issue 59

≠≠≠≠

Healthcare professionals’ perception of psychedelic medicines

For psychedelic medicines to reach as many patients as possible, developers need to secure buy-in at every level of the treatment delivery chain. 

This is particularly true with regards to practitioners on the front line, as these are the individuals that ultimately provide breakthrough therapies over more established, but often less effective, alternatives. 

To identify the sentiment of healthcare providers in the UK, researchers for The Psychedelics as Medicine Report: Third Edition asked for their views on current mental health solutions and perceptions of psychedelic-assisted therapies. 

Read More

AUSTRALIAN REGULATOR REFUSES TO RECLASSIFY PSYCHEDELIC MEDICINES

The Therapeutic Goods Administration has rejected an application to reschedule MDMA and psilocybin for medical use.

Read More

COMPASS PATHWAYS SHARES FURTHER DATA FROM PHASE IIB TRIAL

Open-label study finds psilocybin therapy could be used as adjunctive treatment in combination with SSRIs.

Read More

BUSINESS AND INVESTMENT

Numinus provides Q3 financial update.

Ketamine One provides Q2 2021 financial update.

Alexander Shulgin Research Institute raises C$7.2m in financing round.

Mydecine enters agreement for C$5.5m investment.

Braxia starts clinical trial with psilocybin.

HAVN imports psilocybin from Jamaica into the US.

Field Trip to provide facilities and team for psychedelic research.

‘The public is being primed to feel groovy about psychedelic drugs.’

atai founder holds onto stake despite poor six months.

Psychedelics business takes off amid culture clash.

Cybin files patent for deuterated forms of DMT and 5-MeO-DMT.

Emyria shares results from MDMA analogue screening.

BetterLife Pharma shares preclinical trial data.

PharmaTher provides update on LSD patch.

MINDCURE appoints Dr Sagman as Chief Medical Officer.

The functional and psychedelic mushroom industry is booming.

The Psychedelics as Medicine Report: Third Edition was powered by Blossom, the psychedelic industry’s largest database of market intelligence.

Blossom supports the development of the sector by providing data on companies, their research and clinical trials, empowering operators and policymakers to make informed decisions.

Subscribe to the newsletter

SCIENCE AND RESEARCH

Blossom research briefing: eating disorders.

A kind of magic? The potential of psychedelics.

Psychedelics for mental illness.

Harnessing psychedelics for healing.

Psychedelic drugs and psychotherapy.

REGULATION AND LEGISLATION

Why psychedelics are not the next cannabis.

Three more Canadians receive legal access to psilocybin mushrooms.

New York lawmaker files bill to legalise psilocybin-assisted therapy.

KPBS: legalising psychedelics in California.

Partner with us